The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bispecific Antibodies for Cancer Market Research Report 2025
Synopsis
Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy.
The global Bispecific Antibodies for Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Bispecific Antibodies for Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bispecific Antibodies for Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Bispecific Antibodies for Cancer include Amgen, Astella Pharma, Ben Kang Biopharmaceutical (Shenzhen), Merus and Regeneron Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Bispecific Antibodies for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bispecific Antibodies for Cancer.
Report Scope
The Bispecific Antibodies for Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bispecific Antibodies for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bispecific Antibodies for Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Astella Pharma
Ben Kang Biopharmaceutical (Shenzhen)
Merus
Regeneron Pharmaceuticals
Segment by Type
CD19/CD3
CD30/CD16A
Segment by Application
Hospital
Pharmaceutical Companies
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bispecific Antibodies for Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bispecific Antibodies for Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy.
The global Bispecific Antibodies for Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Bispecific Antibodies for Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bispecific Antibodies for Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Bispecific Antibodies for Cancer include Amgen, Astella Pharma, Ben Kang Biopharmaceutical (Shenzhen), Merus and Regeneron Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Bispecific Antibodies for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bispecific Antibodies for Cancer.
Report Scope
The Bispecific Antibodies for Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bispecific Antibodies for Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bispecific Antibodies for Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Astella Pharma
Ben Kang Biopharmaceutical (Shenzhen)
Merus
Regeneron Pharmaceuticals
Segment by Type
CD19/CD3
CD30/CD16A
Segment by Application
Hospital
Pharmaceutical Companies
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bispecific Antibodies for Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bispecific Antibodies for Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Bispecific Antibodies for Cancer Market Overview
1.1 Product Overview and Scope of Bispecific Antibodies for Cancer
1.2 Bispecific Antibodies for Cancer Segment by Type
1.2.1 Global Bispecific Antibodies for Cancer Market Value Comparison by Type (2024-2030)
1.2.2 CD19/CD3
1.2.3 CD30/CD16A
1.3 Bispecific Antibodies for Cancer Segment by Application
1.3.1 Global Bispecific Antibodies for Cancer Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Pharmaceutical Companies
1.3.4 Other
1.4 Global Bispecific Antibodies for Cancer Market Size Estimates and Forecasts
1.4.1 Global Bispecific Antibodies for Cancer Revenue 2019-2030
1.4.2 Global Bispecific Antibodies for Cancer Sales 2019-2030
1.4.3 Global Bispecific Antibodies for Cancer Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Bispecific Antibodies for Cancer Market Competition by Manufacturers
2.1 Global Bispecific Antibodies for Cancer Sales Market Share by Manufacturers (2019-2024)
2.2 Global Bispecific Antibodies for Cancer Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Bispecific Antibodies for Cancer Average Price by Manufacturers (2019-2024)
2.4 Global Bispecific Antibodies for Cancer Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Bispecific Antibodies for Cancer, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bispecific Antibodies for Cancer, Product Type & Application
2.7 Bispecific Antibodies for Cancer Market Competitive Situation and Trends
2.7.1 Bispecific Antibodies for Cancer Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bispecific Antibodies for Cancer Players Market Share by Revenue
2.7.3 Global Bispecific Antibodies for Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bispecific Antibodies for Cancer Retrospective Market Scenario by Region
3.1 Global Bispecific Antibodies for Cancer Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Bispecific Antibodies for Cancer Global Bispecific Antibodies for Cancer Sales by Region: 2019-2030
3.2.1 Global Bispecific Antibodies for Cancer Sales by Region: 2019-2024
3.2.2 Global Bispecific Antibodies for Cancer Sales by Region: 2025-2030
3.3 Global Bispecific Antibodies for Cancer Global Bispecific Antibodies for Cancer Revenue by Region: 2019-2030
3.3.1 Global Bispecific Antibodies for Cancer Revenue by Region: 2019-2024
3.3.2 Global Bispecific Antibodies for Cancer Revenue by Region: 2025-2030
3.4 North America Bispecific Antibodies for Cancer Market Facts & Figures by Country
3.4.1 North America Bispecific Antibodies for Cancer Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Bispecific Antibodies for Cancer Sales by Country (2019-2030)
3.4.3 North America Bispecific Antibodies for Cancer Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Bispecific Antibodies for Cancer Market Facts & Figures by Country
3.5.1 Europe Bispecific Antibodies for Cancer Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Bispecific Antibodies for Cancer Sales by Country (2019-2030)
3.5.3 Europe Bispecific Antibodies for Cancer Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bispecific Antibodies for Cancer Market Facts & Figures by Country
3.6.1 Asia Pacific Bispecific Antibodies for Cancer Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Bispecific Antibodies for Cancer Sales by Country (2019-2030)
3.6.3 Asia Pacific Bispecific Antibodies for Cancer Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Bispecific Antibodies for Cancer Market Facts & Figures by Country
3.7.1 Latin America Bispecific Antibodies for Cancer Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Bispecific Antibodies for Cancer Sales by Country (2019-2030)
3.7.3 Latin America Bispecific Antibodies for Cancer Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Bispecific Antibodies for Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa Bispecific Antibodies for Cancer Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Bispecific Antibodies for Cancer Sales by Country (2019-2030)
3.8.3 Middle East and Africa Bispecific Antibodies for Cancer Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Bispecific Antibodies for Cancer Sales by Type (2019-2030)
4.1.1 Global Bispecific Antibodies for Cancer Sales by Type (2019-2024)
4.1.2 Global Bispecific Antibodies for Cancer Sales by Type (2025-2030)
4.1.3 Global Bispecific Antibodies for Cancer Sales Market Share by Type (2019-2030)
4.2 Global Bispecific Antibodies for Cancer Revenue by Type (2019-2030)
4.2.1 Global Bispecific Antibodies for Cancer Revenue by Type (2019-2024)
4.2.2 Global Bispecific Antibodies for Cancer Revenue by Type (2025-2030)
4.2.3 Global Bispecific Antibodies for Cancer Revenue Market Share by Type (2019-2030)
4.3 Global Bispecific Antibodies for Cancer Price by Type (2019-2030)
5 Segment by Application
5.1 Global Bispecific Antibodies for Cancer Sales by Application (2019-2030)
5.1.1 Global Bispecific Antibodies for Cancer Sales by Application (2019-2024)
5.1.2 Global Bispecific Antibodies for Cancer Sales by Application (2025-2030)
5.1.3 Global Bispecific Antibodies for Cancer Sales Market Share by Application (2019-2030)
5.2 Global Bispecific Antibodies for Cancer Revenue by Application (2019-2030)
5.2.1 Global Bispecific Antibodies for Cancer Revenue by Application (2019-2024)
5.2.2 Global Bispecific Antibodies for Cancer Revenue by Application (2025-2030)
5.2.3 Global Bispecific Antibodies for Cancer Revenue Market Share by Application (2019-2030)
5.3 Global Bispecific Antibodies for Cancer Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Bispecific Antibodies for Cancer Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Bispecific Antibodies for Cancer Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Astella Pharma
6.2.1 Astella Pharma Corporation Information
6.2.2 Astella Pharma Description and Business Overview
6.2.3 Astella Pharma Bispecific Antibodies for Cancer Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Astella Pharma Bispecific Antibodies for Cancer Product Portfolio
6.2.5 Astella Pharma Recent Developments/Updates
6.3 Ben Kang Biopharmaceutical (Shenzhen)
6.3.1 Ben Kang Biopharmaceutical (Shenzhen) Corporation Information
6.3.2 Ben Kang Biopharmaceutical (Shenzhen) Description and Business Overview
6.3.3 Ben Kang Biopharmaceutical (Shenzhen) Bispecific Antibodies for Cancer Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Ben Kang Biopharmaceutical (Shenzhen) Bispecific Antibodies for Cancer Product Portfolio
6.3.5 Ben Kang Biopharmaceutical (Shenzhen) Recent Developments/Updates
6.4 Merus
6.4.1 Merus Corporation Information
6.4.2 Merus Description and Business Overview
6.4.3 Merus Bispecific Antibodies for Cancer Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merus Bispecific Antibodies for Cancer Product Portfolio
6.4.5 Merus Recent Developments/Updates
6.5 Regeneron Pharmaceuticals
6.5.1 Regeneron Pharmaceuticals Corporation Information
6.5.2 Regeneron Pharmaceuticals Description and Business Overview
6.5.3 Regeneron Pharmaceuticals Bispecific Antibodies for Cancer Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Regeneron Pharmaceuticals Bispecific Antibodies for Cancer Product Portfolio
6.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bispecific Antibodies for Cancer Industry Chain Analysis
7.2 Bispecific Antibodies for Cancer Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bispecific Antibodies for Cancer Production Mode & Process
7.4 Bispecific Antibodies for Cancer Sales and Marketing
7.4.1 Bispecific Antibodies for Cancer Sales Channels
7.4.2 Bispecific Antibodies for Cancer Distributors
7.5 Bispecific Antibodies for Cancer Customers
8 Bispecific Antibodies for Cancer Market Dynamics
8.1 Bispecific Antibodies for Cancer Industry Trends
8.2 Bispecific Antibodies for Cancer Market Drivers
8.3 Bispecific Antibodies for Cancer Market Challenges
8.4 Bispecific Antibodies for Cancer Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
